<DOC>
	<DOCNO>NCT00004095</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine irinotecan gemcitabine treat patient unresectable metastatic solid tumor .</brief_summary>
	<brief_title>Irinotecan Plus Gemcitabine Treating Patients With Unresectable Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) principal toxicity irinotecan gemcitabine patient surgically unresectable metastatic solid tumor . - Determine principal toxicity MTD combination regimen affect drug sequence patient population . - Determine potential gemcitabine alter pharmacokinetic characteristic administer irinotecan patient . - Describe influence effect vary administration sequence combination regimen patient population . - Obtain preliminary data regard efficacy combination regimen patient . OUTLINE : This dose-escalation study . Patients receive irinotecan IV 90 minute follow gemcitabine IV 30 minute day 1 15 . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Once maximum tolerate dose ( MTD ) reach , patient receive subsequent dos inverse sequence combination drug new MTD determine . Cohorts 3-6 patient receive escalate dos irinotecan gemcitabine MTD reach . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow every 3 month death . PROJECTED ACCRUAL : At least 12 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic surgically unresectable solid tumor , receive follow maximum number prior therapy advance disease : Bladder cancer 1 prior therapy Breast cancer 2 prior therapy Colorectal cancer 1 prior therapy Kidney cancer prior therapy Lung cancer 1 prior therapy Pancreatic cancer prior therapy Bidimensionally measurable disease outside previously irradiate field At least 2 cm x 2 cm No known bone metastases CNS involvement allow successfully control surgery radiotherapy require corticosteroid Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL regardless liver involvement secondary tumor SGOT great 3 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis present ) No know Gilbert 's disease Renal : Creatinine great 1.8 mg/dL Calcium le 12.0 mg/dL Cardiovascular : No myocardial infarction within past 6 month No congestive heart failure require therapy Other : No active uncontrolled bacterial , viral ( include HIV ) , invasive fungal infection No psychiatric disorder would prevent compliance No malignancy within past 5 year except adequately treat basal squamous cell skin cancer carcinoma situ cervix No history seizures Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent sargramostim ( GMCSF ) No concurrent immunotherapy Chemotherapy : No prior irinotecan , topotecan , gemcitabine Prior adjuvant chemotherapy allow , least 1 year last dose adjuvant chemotherapy recurrence cancer No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy le 30 % bone marrow No prior whole pelvic radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Other : No concurrent phenytoin , phenobarbital , antiepileptic prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>